Myriad Genetics Inc (MYGN) Dividend History

Myriad Genetics Inc is a biotechnology company specializing in molecular diagnostics and genetic testing. It develops and commercializes tests that assess risk for various diseases, including cancer, women's health conditions, and other hereditary disorders. The company focuses on personalized medicine solutions to help guide clinical decision-making and improve patient outcomes.

322 North 2200 West, Salt Lake City, UT, 84116
Phone: 801-584-3600
Website: https://www.myriad.com

Dividend History

Myriad Genetics Inc currently does not pay dividends

Company News

Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Myriad Genetics, Inc. (MYGN) is facing a securities fraud investigation after its Q1 2025 financial results showed a decline in revenue and reduced guidance for the year, causing a significant drop in its stock price.

Benzinga
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Myriad Genetics, Inc. (MYGN) reported a 3% year-over-year decline in revenue and reduced financial guidance for 2025, causing a 41.3% drop in its stock price. The Law Offices of Howard G. Smith is investigating potential securities fraud claims on behalf of affected investors.

Benzinga
Tissue Diagnostics Market to Reach $12.4 Billion by 2029, Growing at 7.0% CAGR

The global tissue diagnostics market is projected to grow from $8.3 billion in 2023 to $12.4 billion in 2029 at a CAGR of 7.0%, driven by the increasing incidence of cancer, the importance of early cancer testing, and the aging population. The report covers key market segments, trends, and leading companies in this space.

GlobeNewswire Inc.

Featured Companies: A ABT BDX BIO BIO.B DHR ILMN PHG QGEN TMO
Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine | DelveInsight

The molecular diagnostics market is experiencing significant growth driven by advancements in technology, increasing demand for personalized medicine, and the rising prevalence of chronic diseases. Innovations such as next-generation sequencing (NGS) and PCR-based testing are expanding the scope of molecular diagnostics, enabling early detection and more accurate diagnoses.

GlobeNewswire Inc.

Featured Companies: A ABT DHR EXAS ILMN MDXH QGEN TMO
Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of ~17% by 2032 with Advancements in Non-Invasive Testing | DelveInsight

The liquid biopsy market in cancer diagnostics is experiencing rapid growth due to advancements in non-invasive testing technologies, increasing cancer prevalence, and continuous innovations in genomics and biotechnology.

GlobeNewswire Inc.

Featured Companies: EXAS TMO

Dividend data last updated 06/07/2025 14:54:23 UTC